A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-kappa B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Ga Bin | - |
dc.contributor.author | Chung, Yoon Hee | - |
dc.contributor.author | Jeong, Jee-Yeong | - |
dc.contributor.author | Kim, Daejin | - |
dc.date.available | 2019-03-08T08:56:43Z | - |
dc.date.issued | 2017-05 | - |
dc.identifier.issn | 1019-6439 | - |
dc.identifier.issn | 1791-2423 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/4498 | - |
dc.description.abstract | Epstein-Barr virus (EBV) infection is closely related to carcinogenesis of various cancers, and is also associated with the development of drug resistance in cancer stem cells. However, in EBV-positive cancer cells, the mechanistic details of the downstream signaling and the connection of PI3K with the NF-kappa B pathway for development of drug resistance remain controversial. Diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM) cells infected by EBV display drug resistance-related proteins (MDR1, MRP1 and MRP2) and stem cell markers (OCT4 and SOX2). EBV-infected HT (HT/EBV) and H929 (H929/EBV) cells activated p110 delta expression, but downregulated the expression of p110 alpha and p110 beta. A combination of CAL-101, a p110 delta-specific inhibitor, with bortezomib treatment of HT/EBV cells synergistically suppressed proliferation, reduced levels of drug resistance-related proteins, activated caspase cleavage and recovered expression of p110 alpha/p110 beta. Additionally, co-treatment with CAL-101 and bortezomib attenuated the expression of OCT4 and SOX2 via inhibition of activated NF-kappa B. Co-treatment with CAL-101 and bortezomib also attenuated drug resistance and NF-kappa B activity of EBV-infected H929 cells. Our results provide supportive evidence for the clinical application of CAL-101 and bortezomib to treat EBV-infected hematologic cancer. | - |
dc.format.extent | 10 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.title | A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-kappa B | - |
dc.type | Article | - |
dc.identifier.doi | 10.3892/ijo.2017.3923 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF ONCOLOGY, v.50, no.5, pp 1711 - 1720 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000400629600025 | - |
dc.identifier.scopusid | 2-s2.0-85018488285 | - |
dc.citation.endPage | 1720 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 1711 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF ONCOLOGY | - |
dc.citation.volume | 50 | - |
dc.type.docType | Article | - |
dc.publisher.location | 그리이스 | - |
dc.subject.keywordAuthor | CAL-101 | - |
dc.subject.keywordAuthor | bortezomib | - |
dc.subject.keywordAuthor | phosphoinositide 3-kinase | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordAuthor | cancer stem cell | - |
dc.subject.keywordAuthor | Epstein-Barr virus | - |
dc.subject.keywordPlus | EPSTEIN-BARR-VIRUS | - |
dc.subject.keywordPlus | CHRONIC LYMPHOCYTIC-LEUKEMIA | - |
dc.subject.keywordPlus | MEMBRANE-PROTEIN 1 | - |
dc.subject.keywordPlus | MULTIPLE-MYELOMA | - |
dc.subject.keywordPlus | PHOSPHOINOSITIDE 3-KINASE | - |
dc.subject.keywordPlus | TYROSINE KINASE | - |
dc.subject.keywordPlus | P110 DELTA | - |
dc.subject.keywordPlus | LYMPHOMA | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.